New phase I trials are currently active: combination with pemetrexed in advanced solid tumors, (ClinicalTrials.gov identifier: NCT03023319, 2020 recruiting); combination with palbocicilib and fulvestrant for HR+Her2- advanced breast cancer refractory to an aromatase Inhibitor and a Cdk4/6 inhibitor (ClinicalTrials.gov identifier: NCT03854903, 2020 recruiting). This evidence concerns the gene ERBB2 and breast carcinoma.